Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development

Tue Jun 7, 11:00 AM - Wed Jun 8, 5:15 PM, 2022 (EDT)


Video of the workshop is available at the links below:

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development (Day 1) (June 7, 2022)

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development (Day 2) (June 8, 2022)

About the Workshop

The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) program is hosting a two-day workshop that will cover a broad range of critical concepts, including practical approaches and best practices, for developing standardized 3D cellular assays with the hope of helping the community to successfully develop therapeutics for future pandemic threats. This workshop is jointly organized by NCATS, the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation. The overall goal of this workshop is to help scientists establish robust, reproducible, scalable, consistent, advanced 3D tissue models to study pandemic threat viruses.


  • Introduce participants to the available 3D tissue models and discuss challenges in building these models as well as their utility and limitations.
  • Provide case studies on how these available 3D tissue models have been utilized in antiviral drug discovery and development as well as tools for understanding and modeling infectious diseases, including studying viral infection and pathogenesis.
  • Provide guidelines and considerations for developing robust and reproducible 3D tissue models that can be used for testing therapeutics.
  • Discuss challenges in affordability, accessibility, transferability, and reproducibility of these 3D tissue models and the need to set standards on utilization and readouts.
  • Discuss the advantages vs disadvantages of these 3D tissue models.
  • Generate a roadmap to help scientists develop robust and reproducible 3D tissue models to study viruses.


Day 1 Agenda

Day 2 Agenda

Download the agenda

About the Assay Guidance Manual

The Assay Guidance Manual (AGM) is a free, best-practices online resource devoted to the successful development of robust, early-stage drug discovery assays.

The manual was originally developed to provide step-by-step guidance based on experiential knowledge from drug developers for planning and executing projects in high-throughput screening, lead optimization and early phases of drug development. The AGM has now been expanded into a unique, user-friendly collection of over 50 chapters of well-tested knowledge, much of which is being documented for the first time. Methods outlined in the manual address appropriate statistical ways to analyze assay results and accommodate minor changes to assay protocols to ensure robustness.

Investigators worldwide can use the manual to design biologically and pharmacologically relevant assays for high-throughput screening and lead optimization to evaluate collections of molecules that modulate the activity of biological targets, pathways and cellular phenotypes.

The National Center for Advancing Translational Sciences (NCATS) manages the content of the manual with input from industry, academia and government experts. More than 100 authors from around the world have contributed content to this free resource, which is updated regularly and housed by the National Library of Medicine. The chapters have PubMed citations for the contributing authors.

Workshop Organizing Committee

Rodolfo Alarcon, NIAID, NIH Abigail Grossman, NCATS, NIH
Kyle Brimacombe, NCATS, NIH Matthew D. Hall, NCATS, NIH
Mindy Davis, NIAID, NIH Robert Jordan, Bill & Melinda Gates Foundation
Ken Duncan, Bill & Melinda Gates Foundation Emily M. Lee, NCATS, NIH
Ann E. Eakin, NIAID, NIH Sarine Markossian, NCATS, NIH
Marc Ferrer, NCATS, NIH Thames Pickett, NIAID, NIH
Stephanie Ford-Scheimer, NCATS, NIH Mark Williams, NIAID, NIH

’Bill & Melinda Gates Foundation’ is a registered trademark of the Bill & Melinda Gates Foundation in the United States and is used with permission.

The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Ann E. Eakin

Senior Scientific Officer, Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH

Anthony Atala

Link Professor and Director, Wake Forest Institute for Regenerative Medicine

Calvin Kuo

D’Ambrogio Professor of Medicine, Stanford University School of Medicine

Christine Mummery

Professor of Developmental Biology, Dept. of Anatomy & Embryology, Leiden University Medical Center

Donald E. Ingber

Founding Director, Wyss Institute for Biologically Inspired Engineering at Harvard University, Judah Folkman Professor of Vascular Biology, Harvard Medical School & Vascular Biology Program, Boston Children’s Hospital, Hansjörg Wyss Professor of Bioinspired Engineering, Harvard School of Engineering and Applied Sciences

Edwin A. Rosado-Olivieri

Vice President, RumiViro

Emily Erbelding

Director, Division of Microbiology and Infectious Diseases, NIAID/NIH

Emily M. Lee

Staff Scientist I, Functional Group Lead, Advanced Models & Cell Discovery, Antiviral Program for Pandemics, Division of Preclinical Innovation, 3D Tissue Bioprinting Lab, Early Translation Branch, National Center for Advancing Translational Sciences, National Institutes of Health

Evi Struble

Research Pharmacologist, Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies Center, for Biologics Evaluation and Research, U.S. Food and Drug Administration

Hans Clevers

Head of Pharma Research and Early Development, Member of the Enlarged Executive Committee, F. Hoffmann-La Roche Ltd

Jeffrey T. Borenstein

Group Leader, Bioengineering, Draper

Jia Zhu

Associate Professor, Vaccine and Infectious Disease Division, Fred Hutch Cancer Center; Research Associate Professor, Department of Laboratory Medicine and Pathology, University of Washington School of Medicine

Joni L. Rutter

Acting Director, National Center for Advancing Translational Sciences, National Institutes of Health

Lee Gehrke

Professor, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Department of Microbiology, Harvard Medical School

Linda Griffith

School of Engineering Professor of Teaching innovation, Department of Biological Engineering, and Director, Center for Gynepathology Research, MIT

Marc Ferrer

Director, 3D Tissue Bioprinting Laboratory, NCATS

Nicole C. Kleinstreuer

Acting NICEATM Director, NIEHS

Robert Jordan

Senior Program Officer, Bill and Melinda Gates Foundation

Sara Cherry

Professor of Pathology of Laboratory Medicine, Microbiology and Biochemistry and Molecular Biophysics Scientific Director, High-throughput Screening Core Director, Program for Chemogenomic Discovery

Sarine Markossian

Editor-in-Chief, Assay Guidance Manual; Lead, Translational Science Resources Program, NCATS

Sashi Ramani

Assistant Professor, Molecular Virology and Microbiology, Baylor College of Medicine

Simon Funnell

Scientific Leader, UK Health Security Agency

Thomas Hartung

Doerenkamp-Zbinden Chair for Evidence-based Toxicology

Zhengpeng (Jason) Wan

Postdoc Associate
  • Abigail Grossman